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ABSTRACT
Cost-Effectiveness Analysis of Tisagenlecleucel, Blinatumomab, and Clofarabine for Treatment
of B-cell Precursor Acute Lymphoblastic Leukemia
by Kamron Lotfi
Introduction
Acute lymphoblastic leukemia (ALL) is a common type of adolescent and young adult
leukemia in the United States (U.S.). Patients who are refractory or relapsed after receiving two
or more lines of systemic therapy have the option of taking tisagenlecleucel. Due to the high cost
of this treatment, a cost-effectiveness analysis was performed to assess the treatments for
tisagenlecleucel, clofarabine combination, and blinatumomab.
Objectives
The objective of this study is to evaluate the cost-effectiveness of tisagenlecleucel;
clofarabine, etoposide, cyclophosphamide; and blinatumomab for the treatment of relapserefractory ALL for adolescents and young adults from the U.S. health care payer perspective.
Material and Methods
Clinical data were collected from the FDA databases, RedBook online, National
Institutes of Health (NIH) research database, PubMed database, and clinicaltrials.gov. The cost
information was extracted from the Redbook and published studies. The cost-effective analysis
was performed using TreeAge Pro (Healthcare Version) version 2021.
Results
The incremental cost of tisagenlecleucel was $520,050 compared to blinatumomab. The
base case showed tisagenlecleucel effectiveness was the highest at 19.284, and blinatumomab
effectiveness was 12.580. Tisagenlecleucel had an ICER of $77,573. The probability sensitivity
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analysis showed that tisagenlecleucel was 63.1% of the time, and clofarabine combination was
dominated by tisagenlecleucel and blinatumomab.
Conclusions
Tisagenlecleucel and blinatumomab dominated the clofarabine combination. According
to the results of the sensitivity analysis, tisagenlecleucel was more cost-effective 63.1% of the
time. Blinatumomab was more cost-effective at a lower WTP and 35.8% of the time.
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1. INTRODUCTION

In the past decade, breakthroughs in cancer drug research of the human immune system
resulted in the development of a new category of cancer drugs called immunotherapy. There are
different types of immunotherapy cancer treatments, including immune checkpoint inhibitors, Tcell transfer therapy, monoclonal antibodies, treatment vaccines, and immune system
modulators.1,2 Immunotherapy drugs are enhanced to target specific checkpoints in the immune
system and the body's defense systems to tackle the most challenging oncology diseases. 3,4
However, the advancement of immunotherapy still has significant obstacles, including the need
for biomarkers, deficiencies of clinical design to assess safety and efficacy, the incapability to
predict the response of treatment for individual patients, and high cost.5,6 The cost of cancer
immunotherapy is $100,000 or more per patient, roughly two times the United States median
household annual income.7,8 Even though immunotherapy is often covered by health insurance, it
can still be unaffordable to patients due to high out-of-pocket costs.
Non-Hodgkin lymphoma (NHL) starts inside white blood cells called lymphocytes that
can grow in areas of the immune system, such as the lymph nodes.9 NHL accounts for an
estimate of 3% for cancer-related deaths and is the seventh leading cause of new cancer cases in
the United States.10 In 2020, there were 74,200 diagnosed NHL cases and 19,970 deaths from
this disease.11
Acute lymphoblastic leukemia (ALL) is one of the most common types of cancer in the
white blood cells by overproducing immature lymphocytes in the bone marrow diagnosed in the
pediatric population.12 Children who have ALL have a high number of
lymphoblasts/lymphocytes. When this occurs, the number of cancerous cells outnumber the
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number of white blood cells. ALL is a B-cell lymphoma disease that occurs from somatic genetic
alterations, which include chromosome number change/rearrangement.13 Symptoms of ALL are
anemia, bruising, bleeding, and fatigue. ALL is the most common cancer in children and young
adults, with around 54.3% of new cases under 20.14 ALL accounts for around 20% of pediatric
cancer for children.15 ALL occurs mainly in children, representing 80% of cases; however, adults
can be susceptible to this disease with a low cure rate of 40%.26 According to the National
Cancer Institute, there were over 6,100 new cases of ALL and 1,500 deaths in 2020 in the US.17
Treatment can bring 95% complete remission of patients, and since 1948, there has been
a significant 80% increase in survival rate in children.18,19 However, the survival rate can
drastically decrease on patients who do not respond to initial chemotherapy treatment.
Adolescent or young adults with standard-risk ALL often receive three drugs for the first
month of treatment as first-line therapy. Patients with standard-risk ALL would typically receive
the chemotherapy drugs L-asparaginase and vincristine and the steroid drug dexamethasone.20,21
Treatment will vary according to the cancer risk. Patients who are relapsed or refractory need to
use a second-line therapy that consists of chemotherapies such as blinatumomab and clofarabine
combination (etoposide and cyclophosphamide).22 Patients who are refractory or relapsed after
receiving two or more lines of systemic therapy can use tisagenlecleucel that is considered the
last treatment option.
Tisagenlecleucel is indicated for adult patients with relapsed or refractory large B-cell
lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma
(DLBCL) not otherwise specified, high-grade B-cell lymphoma, and DLBCL arising from
follicular lymphoma.23,24 Tisagenlecleucel was also approved for relapsed or refractory acute
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lymphoblastic leukemia and for treating pediatric and young adult patients up to 25 years of age
with B-cell acute lymphoblastic leukemia (ALL).25,26 Tisagenlecleucel is given as a single dose
with a wholesale acquisition cost (WAC) of $475,000.27 Despite the high cost of new ALL
treatments, studies assessing their cost-effectiveness are lacking.
Cost-effective analysis of tisagenlecleucel compared to other salvage chemotherapy
treatments for relapsed-refractory ALL has not been published. Due to the limitation of clinical
trials and the high cost of CAR T-cell therapies, questions have been raised on their economic
and clinical value in clinical practice.28
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2. OBJECTIVES
The objective of this study is to evaluate the cost-effectiveness of tisagenlecleucel;
clofarabine, etoposide, cyclophosphamide; and blinatumomab for the treatment of relapserefractory ALL for adolescent and young adult patients from the U.S. health care payer
perspective.
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3. HYPOTHESIS
We hypothesize that tisagenlecleucel is the most cost-effective alternative for treating RRALL for adolescent and young adult patients.
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4. MATERIALS AND METHODS
4.1. Data Sources
Clinical data were collected from the FDA databases, RedBook online, National
Institutes of Health (NIH) research database, PubMed database, and ClinicalTrials.gov. 29,30
ClinicalTrails.gov is managed by the United States National Library of Medicine and the
National Institutes of Health. ClinicalTrials.gov includes information from over 200 countries,
with more than 329,000 trials to date.31
Tisagenlecleucel and salvage chemotherapy treatment AWP and WAC data were
collected from the RedBook online. The information in the RedBook includes the name of the
product, active ingredient, brand or generic status, price start date, orange book code,
formulation, route of administration, dosage unit, average wholesale price (AWP), and wholesale
acquisition cost (WAC).32 Drug manufacturers report the AWP and the WAC. These prices do
not represent the actual net acquisition cost paid in the U.S. but are used for pharmacy
reimbursement purposes. Other cost information was collected from previously published
studies.
4.2 Methods
4.3 Partitioned Survival Model
A cost-effectiveness model using the U.S. health care payer's perspective was constructed
by using TreeAge Pro (Healthcare Version) version 2021 software. The partitioned survival
model (Figure 1) will consist of a cohort for specific states: remission, refractory or relapsed, and
death based on overall survival.
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Relapsed/Refractory
ALL

Remission

Death

Figure 1. States of the partitioned survival model
The partitioned survival model baseline assumptions are that patients had a previous
history of chemotherapy and enter the model at ten years of age. The primary study outcome was
the number of life-years gained over the study time horizon. The incremental life-years gained
were estimated as the difference in life-years gained between the therapeutic alternatives.
The study includes direct healthcare costs related to the alternatives. Indirect costs were
excluded from the analysis. All costs were adjusted to 2020 U.S. dollars using all urban
consumers, not seasonally adjusted, U.S. city average, all items, consumer price index (CPI).
Costs and outcomes were discounted at a 3% annual discount rate.
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The cost and life-years gained over the time horizon were estimated for each treatment. A
cost-effectiveness ratio (CER) was employed to calculate the cost per life-year gained for each
treatment alternative. The lowest cost per life-year treatment was considered as the reference
therapy. When a treatment had a greater cost and effectiveness in relation to the reference, an
incremental cost-effectiveness ratio was performed to determine the additional cost to obtain one
life-year.
The impact of parameter uncertainty was explored by a one-way sensitivity analysis on
each model parameter. A probabilistic sensitivity analysis was conducted to investigate the
combined impact of uncertainty of the variables included in the analysis. Random values were
drawn from the chosen distributions as a second-order Monte-Carlo simulation of 1000 patients
to estimate the mean and 95% confidential intervals (CI) of overall survival probabilities. All
parameters in the model will have correspondingly appropriate distributions. Costs were
randomly drawn from a gamma distribution; the hazard ratio was randomly sampled from a
lognormal distribution. Likewise, binominal data, such as adverse events, were randomly drawn
from a beta distribution.

4.4. Treatment Strategies
The FDA approved three products approved by the FDA for the treatment of ALL in
pediatric patients (Table 1).
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Table 1. Tisagenlecleucel, blinatumomab, and clofarabine FDA-Approved Indications
Generic Name
(Approval Date)
Tisagenlecleucel
(August 30, 2017)

Blinatumomab
(September 1, 2016)
Clofarabine
(December 12, 2004)

Pediatric ALL Indications
Indicated for the treatment of Pediatric and Young Adult Relapsed or
Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (ALL) patients
up to 25 years of age with B-cell precursor acute lymphoblastic
leukemia (ALL) that is refractory or in second or later relapse.
Indicated for the treatment of relapsed or refractory CD19-positive Bcell precursor acute lymphoblastic leukemia (ALL) in adults and
children.
Indicated for the treatment of pediatric patients 1 to 21 years old with
relapsed or refractory acute lymphoblastic leukemia after at least two
prior regimens. This indication is based upon response rate. There are no
trials verifying an improvement in disease-related symptoms or
increased survival with clofarabine injection.

The treatment dosages for tisagenlecleucel, blinatumomab, and clofarabine are described
in Table 2.
Tisagenlecleucel Treatment Process
To prepare tisagenlecleucel, the patient undergoes leukapheresis to obtain peripheral
blood mononuclear cells. Leukapheresis treatment lasts 3 to 6 hours, and within 24 hours, the
blood cells are cryopreserved (Table 3).32 Ex vivo preparation is next conducted for
tisagenlecleucel with autologous T cells. The autologous T cells are transduced to activate T
cells by a lentiviral vector. The process of preparing tisagenlecleucel takes approximately 45
days, and during this time, patients undergo bridging therapy to stop disease progression.32
Lymphodepleting chemotherapy is received by patients two weeks before the infusion of
tisagenlecleucel so the patient can help the proliferation of tisagenlecleucel throughout the body.
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Table 2. Treatment dosages for tisagenlecleucel, blinatumomab, and clofarabine
Name
Tisagenlecleucel
Bridging
chemotherapy
(Given to 87% of
patients prior to
CART)
Lympho-depleting
chemotherapy (given
to 96% of patients
prior to CART)
Lympho-depleting
chemotherapy (given
to 4% of patients
prior to CART)
Blinatumomab
Clofarabine
Combination

Therapy
3.1x106/kg (0.2-5.4 x 106/kg) transfused viable T
cells.
Methotrexate (15mg I.T. x1); Hydrocortisone (15mg
I.T. x1) and cytarabine (30mg I.T. weekly until CSF
clears)
Cytarabine (300mg/ m2 IV x 1) and etoposide
(150mg/ m2 IV x 2) peg asparaginase (25000 units/
m2 IV x 1)
Fludarabine (30mg/ m2 IV x 4), Cyclophosphamide
(500mg/ m2 IV x 2)

Source
Maude et al. (2018)

Cytarabine (500mg/ m2 IV x 2) and etoposide
(150mg/m2 IV x 3)

Maude et al. (2018)

5ug/m2/d x 7 days, then 15ug / m2 / d

Stackelberg et al.
(2016)
Hijiya et al. (2009)

clofarabine (400mg/ m2 IV x 9days), etoposide
(100mg / m2 IV X 9 days), cyclophosphamide
(440mg / m2 x 9 days)

Lin et al. (2018)

Maude et al. (2018)

Table 3. Treatment timeline of tisagenlecleucel
Treatment
Bridging chemotherapy
Days 1-2

Lymphodepleting chemotherapy
Days 3-17

Tisagenlecleucel
Day 20

Dosage
Methotrexate (15mg I.T. x1); Hydrocortisone
(15mg I.T. x1) and cytarabine (30mg I.T.
weekly until CSF clears); Cytarabine (300mg/
m2 IV x 1) and etoposide (150mg/m2 IV x 2)
peg asparaginase (25000 units/ m2 IV x 1)
Fludarabine (30mg/ m2 IV x 4),
Cyclophosphamide(500mg/ m2 IV x 2)
3.1x106/kg (0.2-5.4 x 106/kg) transfused viable
T cells.
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Blinatumomab and Clofarabine combination
Patients who receive blinatumomab and clofarabine and are in remission also receive
post-induction chemotherapy after one year to continue to be in remission (Tables 4 and 5).
Table 4. Treatment timeline for blinatumomab
Cycle

Dosage

Introduction Cycle 1
Days 1-7
Days 8-28
Days 29-42
Induction Cycle 2
Days 1-28
Days 29-42
Consolidation Cycles 3-5
Days 1-28
Days 29-42
Continued Cycles 6-9
Days 1-28
Days 19-84

5ug/m2/d/day
15ug/m2/d/day
14-day treatment-free interval
15ug/m2/d/day
14-day treatment-free interval
15ug/m2/d/day
14-day treatment-free interval
15ug/m2/d/day
56-day treatment-free interval

Table 5. Treatment timeline for clofarabine combination
Cycle
Cycle 1 (9 consecutive days)

Cycle 2 (9 consecutive days)

Dosage
clofarabine (400mg/ m2 IV x 9days),
etoposide (100mg / m2 IV X 9 days),
cyclophosphamide (440mg / m2 x 9 days)
clofarabine (400mg/ m2 IV x 9days),
etoposide (100mg / m2 IV X 9 days),
cyclophosphamide (440mg / m2 x 9 days)
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4.5 Outcomes
Survival data were derived from three clinical trial sources Hijiya et al. (2009), Lin et al.
(2018), Stackelberg et al. (2016), a study assessing the survival of ALL patients in the 10-14
years old range and survival for the general population33.
Tisagenlecleucel overall survival, continued remission, and event-free survival were
obtained from Maude et al. (2018). There were two sets of data used for tisagenlecleucel:
•

Efficacy analysis set: Includes patients that used the drug and excludes patients that
were enrolled in the study but did not qualify for getting the drug because of death,
changes in health status that resulted in exclusion, or problems manufacturing the drug.

•

Enrolled set: includes all the patients enrolled in the clinical trial.

Blinatumomab clinical trial overall survival, continued remission, and event-free survival were
obtained from Stackelberg et al. (2016). Clofarabine combination clinical trial overall survival
curve, continued remission, and event-free survival were obtained from Hijiya et al. (2009).
Kaplan-Meier curves were created for the probability of overall survival, continued
remission, and event-free survival for tisagenlecleucel, blinatumomab, and clofarabine. KaplanMeier curves were created because the estimates of survival data can deal with differing survival
times since not all patients continue throughout the whole study. Also, Kaplan-Meier curves give
a "time to an event" at the respective time interval.
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4.6 Adverse Events
The probability and cost of adverse events were collected from the literature (Table 6).
Table 6. Cost and probabilities per patient for all treatment strategies.12,14,24
Cost and Probabilities

Tisagenlecleucel Blinatumomab Clofarabine
Probabilities of Probabilities of Probabilities of
Adverse Events Adverse Events Adverse Events
Acute Kidney Injury
0.08
0
0.16
ALT or AST Increased
0.1
0.16
0.4
Anemia
0.4
0.36
0.64
Coagulopathy
0
0
0.12
Cytokine Release Syndrome
0.46
0.06
0
Decreased Appetite
0.09
0
0.2
Febrile Neutropenia
0.35
0.17
0.6
Fluid Overload
0.05
0
0
Gingival Bleeding
0
0
0.12
Hepatomegaly
0
0
0
Hyperbilirubinemia
0.11
0
0.12
Hypertension
0
0.06
0
Hypokalemia
0.08
0.17
0.36
Hypophosphatemia
0.08
0
0.12
Hypotension
0.17
0
0.24
Hypoxia
0.11
0
0
Increased Lipase
0
0
0.2
Leukopenia
0.12
0.1
0.16
Nausea
0
0
0.12
Neutropenia
0.04
0.17
0.52
Overall Neurological Events
0.13
0.04
0
Pleural Effusion
0.04
0
0
Pulmonary Edema
0.06
0
0.12
Pyrexia
0.1
0.14
0.16
Rash
0
0
0
Respiratory Distress
0.04
0.01
0
Thrombocytopenia
0.05
0.21
0.64
Typhilis
0
0
0.12
Veno Occlusive Disease
0
0
0.12
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Cost of
Patient
$682.03
$1,544.79
$4,526.60
$296.53
$9,043.81
$445.90
$7,273.80
$30.02
$154.67
$0
$209.23
$41.16
$1,322.66
$306.26
$818.76
$98.97
$275.98
$286.82
$111.64
$4,279.79
$323.20
$51.27
$192.22
$260.28
$0
$13.34
$4,416.20
$60.01
$259.44

4.7 Costs
Costs were acquired from the Red Book, Centers for Medicare and Medicaid Services,
and adjusted to 2020 dollars by the consumer price index (CPI). The direct medical costs include
drug administration, drug product, follow-up care, and adverse events (Tables 7-11).
Table 7. Tisagenlecleucel healthcare costs
Pre-tisagenlecleucel
Bridging chemotherapy
Lymphodepleting chemotherapy
(fludarabine and
cyclophosphamide) 96% patients
Lymphodepleting chemotherapy
(cytarabine and etoposide) 4% of
patients
Treatment cost

Drug and administration at
the hospital
Drug and administration at
hospital
Drug and administration at
the hospital
Drug
Adverse events
IVIG treatment
Drug Administration at
hospital
Health care costs after
treatment per month

Total Cost

Cost
Source
$15,000.00 Lin et al. (2018)
$1,781.49 CMS (2018)

$807.78 CMS (2018)

$475,000.00 Red Book (2021)
$42,769.98 CMS (2018)
$28,818.24 Red Book (2018);
Lin et al. (2018)
$6,331.28 CMS (2018);
Lin et al.(2018)
$8,056.01
$578,564.78

Table 8. Clofarabine combination healthcare costs
Treatment Cost

Drug
Adverse events
Administration at hospital
Health care costs after
treatment per month

Total Cost

Cost
Source
$37,400.00 Lin et al. (2018)
$54,252.52 Lin et al. (2018);
CMS (2018)
$24,342.68 Lin et al. (2018)
$1,964.88 Lin et al. (2018)
$117,960.08
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Table 9. Blinatumomab healthcare costs.
Cost
Treatment Cost

Drug
Adverse events
Administration at
hospital

Source

$43,700.00 Lin et al. (2018)
$16,919.80 Lin et al. (2018); CMS (2018)
$8,187.00 Lin et al. (2018)

Total Cost

$68,806.80

Table 10. Cost of palliative chemotherapy for relapsed/refractory patients.
Cost
Palliative Chemotherapy

Drug

Source

$2,881.82 Lin et al.

Table 11. Cost of individual grade 3-4 adverse events for each treatment strategy.
Adverse Event

Tisagenlecleucel
Cost
$1,706.04
$790.21
$2,591.02
$0
$19,342.28
$834.78
$4,980.92
$600.65
$0

Blinatumomab
Cost
$0
$1,264.33
$2,331.92
$0
$2,522.91
$0
$2,419.30
$0
$0

Clofarabine
Cost
$3,412.08
$3,160.84
$4,145.63
$2,472.47
$0
$1,855.07
$8,538.71
$0
$1,289.62

Hepatomegaly
Hyperbilirubinemia
Hypertension
Hypokalemia

$0
$868.99
$0
$642.04

$0
$0
$686.40
$1,364.33

$0
$947.99
$0
$2,889.16

Hypophosphatemia
Hypotension
Hypoxia
Increased Lipase
Leukopenia

$1,178.58
$1,610.02
$900.21
$0
$688.76

$0
$0
$0
$0
$573.96

$1,767.87
$2,272.97
$0
$1,380.66
$918.34

Acute Kidney Injury
ALT or AST Increased
Anemia
Coagulopathy
Cytokine Release Syndrome
Decreased Appetite
Febrile Neutropenia
Fluid Overload
Gingival Bleeding
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Table 11. Cost of individual grade 3-4 adverse events for each treatment strategy (Cont.)
Nausea
Neutropenia
Overall Neurological Events
Pleural Effusion
Pulmonary Edema
Pyrexia
Rash
Respiratory Distress
Thrombocytopenia
Typhilis
Veno Occlusive Disease
TOTAL

$0
$569.25
$2,272.37
$1,282.46
$641.07
$471.79
$0
$313.94
$484.29
$0
$0
$42,769.66
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$0
$2,419.30
$699.19
$0
$0
$660.51
$0
$78.49
$2,034.01
$0
$0
$17,054.65

$930.83
$7,400.22
$0
$0
$1,282.15
$754.86
$0
$0
$6,198.89
$500.39
$2,163.20
$54,281.95

5. RESULTS

5.1 Patient Characteristics
The patient characteristics varied according to the clinical trial. Tisagenlecleucel patients
were between 3 to 21 years of age (Table 12). There were 47% females and 53% males in the
clinical trial. There were 92 patients enrolled in the study, and 75 underwent infusion
Table 12. Patient population of tisagenlecleucel clinical trial data (ELIANA). 12
Patient Population tisagenlecleucel

0-45 days before receiving
tisagenlecleucel
Dropout/Censored
Death
After receiving tisagenlecleucel
Dropout/Censored
Death
Age, years
3 to 21
Sex
Female
Male
Status
Relapse/Refractory
Remission
Prior HSCT

Efficacy
Analysis Set
(n=107)

Enrolled Set
(n=92)

Underwent
Infusion (n=75)

-

10 (11)
7 (8)

-

-

-

16 (21)
11 (15)

107 (100)

92 (100)

75 (100)

-

-

35 (47)
40 (53)

-

-

9 (12)
61 (81)
46 (61)
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Table 13. Patient population of blinatumomab clinical trials (n=70). 24
Variable
Sex
Male
Female
Age group, years
<2
2 to 6
7 to 17
Prevous HSCT
Yes
No
Previous Relapses
0
1
2
≥3
Status
Relapse/Refractory
Remission
Dropout/Censored
Death

n (%)
47 (67)
25(33)
10 (14)
20 (29)
40 (57)
40 (57)
30 (43)
2 (3)
31 (44)
29 (41)
8 (11)
39 (56)
27 (39)
16 (23)
27 (39)

Blinatumomab patient age range was less than 2 years to 17 years (Table 13). The patient
population of blinatumomab was 67% male and 33% female, with 70 total patients enrolled.
Clofarabine combination patients were between 1 year to 21 years of age (Table 14). The patient
population was 64% male and 36% female, with 25 patients enrolled.
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Table 14. Patient population of clofarabine with etoposide and
cyclophosphamide clinical trials (N=25).12
Characteristic
Age (years)
Median
Range
Sex
Male
Female
Prior regimens
Median
Range
1 regimen
2 regimen
3 regimen
Status
Relapse/Refractory
Remission
Prior HSCT
Dropout/Censored
Death

n (%)
14
1 to 21
16 (64)
9 (36)
2
1 to 3
4 (16)
14 (56)
15 (60)
15 (60)
7 (28)
4 (16)
2 (8)
7 (28)
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5.2 Outcomes

Tisagenlecleucel Kaplan-Meier plot (Figure 2) 95% confidence interval at month 26 was
0.421[0.203, 0.626]. Blinatumomab Kaplan-Meier plot (Figure 3) 95% confidence interval at
month 26 was 0.246[0.146, 0.359]. Clofarabine combination (Figure 4) 95% confidence interval
at month 36 was 0.211[0.0533, 0.439]. The partitioned model survival curves are displayed in
figures 5-7.

Figure 2. Tisagenlecleucel overall patient survival.12

20

Figure 3. Blinatumomab overall patient survival.24

Figure 4. Clofarabine overall patient survival.12
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Figure 5. Partitioned survival model curve of tisagenlecleucel.

Figure 6. Partitioned survival model curve of blinatumomab.
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Figure 7. Partitioned survival model curve of clofarabine combination.

5.3. Cost-Effectiveness and Incremental Cost-Effectiveness
In the base case scenario, tisagenlecleucel effectiveness was 19.284 years, blinatumomab
was 12.580 years, and clofarabine combination was 7.566 years. Blinatumomab and
tisagenlecleucel were both undominated, and the clofarabine combination was dominated (Table
15).
A partitioned survival analysis model followed the patient cohort thought time as they
moved through relapsed/refractory or remission states for tisagenlecleucel, blinatumomab, and
clofarabine combination. The cost-effectiveness analysis showed that clofarabine was not costeffective (Figure 8).
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Table 15. Incremental cost, incremental effectiveness, ICER for tisagenlecleucel,
blinatumomab, and clofarabine combination
Drugs

Cost

Excluding Dominated
Blinatumomab
$71,701
Tisagenlecleucel
$591,751
All Therapies
Blinatumomab
$71,701
Clofarabine
$139,225
Tisagenlecleucel
$591,751

Incremental
Cost

Effectiveness Incremental ICER
Effectiveness

$520,050

12.580
19.284

6.704

$77,573

$67,524
$520,050

12.580
7.566
19.284

-5.014
6.704

-$13,467
$77,573

Figure 8. Cost-effectiveness analysis results for all treatments.
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5.4 Probabilistic Sensitivity Analysis
The PSA was conducted using the 95% confidence intervals for the overall survival and
remission for all treatments. Clofarabine was dominated while tisagenlecleucel and
blinatumomab remained the strategy with the higher cost and effectiveness. The PSA found that
tisagenlecleucel was more cost-effective 63.1% and blinatumomab 35.8% of the time.
The PSA results found that tisagenlecleucel and blinatumomab were both undominated,
and clofarabine combination was dominated. The PSA found that tisagenlecleucel was costeffective 63.1% of the time with a willingness to pay $100,000. Even though tisagenlecleucel
was more cost-effective, blinatumomab was more cost-effective 35.8% of the time (Figure 9-12).
The Monte Carlo acceptability at the WTP of 100,000 showed that tisagenlecleucel was
more cost-effective 63.1% of the time when compared to blinatumomab (35.8%) and clofarabine
(1.9%) (Figure 13). According to the cost-effectiveness acceptability curve for the WTP,
tisagenlecleucel was more favorable at a WTP higher than $80,000. The blinatumomab WTP
was more favorable below a WTP of 80,000, and clofarabine was not favorable under any WTP.

25

Figure 9. One-way cost-effectiveness sensitivity analysis of tisagenlecleucel

Figure 10. One-way cost-effectiveness sensitivity analysis of blinatumomab
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Figure 11. Monte Carlo acceptability at WTP of 100,000 for all treatment alternatives

Figure 12. Cost-effectiveness acceptability curve of tisagenlecleucel, blinatumomab,
and clofarabine.
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Figure 13. Monte Carlo probability distribution INMB of tisagenlecleucel vs.
blinatumomab.
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6. DISCUSSION

Our analysis indicates that tisagenlecleucel has higher overall survival than
blinatumomab and clofarabine combination in patients with ALL.
This study presented that the effectiveness for tisagenlecleucel was 19.284 and had an
ICER of $77,573 for an additional L.Y. gained. Blinatumomab had an effectiveness of 12.580,
and the dominated treatment clofarabine had an effectiveness of 7.566. Tisagenlecleucel had the
highest cost in the partitioned survival model, with $591,751 and an ICER of $77,573.
Tisagenlecleucel and blinatumomab were both undominated, and the clofarabine
combination was dominated for the base case analysis. The probabilistic sensitivity analysis
confirmed that tisagenlecleucel and blinatumomab were undominated, and the clofarabine
combination was dominated.
According to the probabilistic sensitivity analysis, tisagenlecleucel was the most costeffective alternatives 63.1% of the time. These results are similar to those of other studies that
also found that tisagenlecleucel was more cost-effective the majority of the time (Furzer et al.,
2020). Clofarabine was dominated by tisagenlecleucel and blinatumomab and was the least costeffective as found in previously published studies (Locatelli et al, 2009).

The available evidence about the cost, efficacy, and safety of tisagenlecleucel,
blinatumomab and clofarabine is very limited. There is a need for more studies evaluating the
long-term effect of the available therapies for the treatment of ALL to get the evidence necessary
for the appropriate utilization of those expensive drugs.
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7. LIMITATIONS
This study has some limitations. The model evaluates differences of alternative therapy
pathways from a set of assumptions and does not portray the progression of RR-ALL patients in
clinical practice. Patients can develop RR-ALL during their lifetime. The available data only
contains outcomes for up to 34 months. Since the clinical trials are still ongoing, other clinical
information on outcomes and safety was collected from published studies from the United States
and other countries. The clinical trials used in this study had different disease states, previous
treatments, and patient demographic characteristics. The difference is significant for age because
survival rates decline with the increase in age.30

The patient characteristics included in this study were different for the clinical trials of
the products tisagenlecleucel, blinatumomab, and clofarabine. The clinical trials for
blinatumomab and clofarabine included patients less than 2 years of age, unlike while the clinical
trials for tisagenlecleucel included patients starting at 3 years of age. The disease states of the
patients included in the clinical trials were also different, with tisagenlecleucel clinical trials
having a higher percentage of patients in remission at the start of the study (Table 14). Nonhealth care and indirect costs were excluded from the analysis. The life years were not adjusted
by the quality of life (quality-adjusted life years) due to the limitations of the clinical trials and
lack of information about the qualify of life.
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8. CONCLUSIONS

The base case showed that tisagenlecleucel effectiveness was the highest at 19.284, and
blinatumomab was the second-highest at 12.580. Tisagenlecleuel was cost-effective with an
ICER of $77,573. Clofarabine was dominated and was the worst out of the three treatment
strategies for cost-effectiveness. The results of the PSA showed that tisagenlecleucel was always
not the most cost-effective. Blinatumomab was more cost-effective when it was 35.8% higher
than the base case. Tisagenlecleuel was more cost-effective at a higher WTP, and blinatumomab
was more cost-effective at a lower WTP. Tisagenlecleucel was more cost-effective 63.1% of the
time, and blinatumomab was more cost-effective 35.8% of the time.
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